Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

EBSNYSE / NASDAQHealthcareSmall cap

$5.05-$0.10 (-1.9%)

Last close · Data as of Nov 20, 2026

Market cap
$435.5M
P/E
8.3x
EV / EBITDA
3.4x
Revenue
$705.2M
Net margin
7.5%
ROCE
13.0%

-44.4% over the last year

Emergent BioSolutions Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-19.7%
3M
+4.8%
6M
-38.0%
1Y
-44.4%
5Y
-87.4%

52-week range

Day change -$0.10 (-1.9%) from $5.15 to $5.05 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in EBS, bought on each weekday since 2021.

News & filings

What Emergent BioSolutions filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -39.5% to 10.1% between fiscal 2024 and fiscal 2025.

Concerns (1)

  • The price is 33.4% below its 200-day average, and the 50-day average is below the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.

Read moreShow less

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Sector
Healthcare
Shares outstanding
52.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$435.5M
P/E
8.3x
P/B
0.8x
EV / EBITDA
3.4x
EV / Sales
1.1x
P/S
0.6x
52-week high
$13.90
52-week low
$4.45

Profitability

Operating margin
15.9%
Net margin
7.5%
EBITDA margin
33.7%
ROE
10.1%
ROCE
13.0%
ROIC
10.4%
ROA
4.0%
Asset turnover
0.53

Growth

Revenue
$705.2M
Revenue growth, 1Y
-30.4%
Revenue CAGR, 3Y
-13.1%
Net profit growth, 1Y
-127.6%
Free cash flow
$156.8M

Solvency

Current ratio
5.01
Debt / Equity
1.09
Debt / Assets
0.43
CFO / Net profit
3.24
Cash / Market cap
47.2%

Where the revenue went

Of every $100 of FY2025 revenue, $7 was left as net income.

Emergent BioSolutions Inc. income statement flow, FY2025
Emergent BioSolutions Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$326.2M
RevenueGross profit$379.0M
Gross profitResearch and development$53.2M
Gross profitSelling, general and administrative$186.1M
Gross profitOther operating expenses$27.4M
Gross profitOperating income$112.3M
Operating incomePretax income$82.8M
Operating incomeInterest and other expense$29.5M
Pretax incomeTax and other$30.2M
Pretax incomeNet income$52.6M

Revenue and net profit

Revenue fell 30.4% in FY2025; net profit is the dashed line.

Emergent BioSolutions Inc. revenue and net profit by fiscal year
Emergent BioSolutions Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.1B-$211.6M
FY2023$1.0B-$760.5M
FY2024$1.0B-$190.6M
FY2025$705.2M$52.6M

Cash flows

FY2025: $170.6M from operations, $156.8M free after investment (dashed).

Emergent BioSolutions Inc. operating and free cash flow by fiscal year
Emergent BioSolutions Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$34.1M-$149.9M
FY2023-$206.3M-$257.9M
FY2024$58.7M$35.8M
FY2025$170.6M$156.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$705.2M-30.4%1Y
EBITDA
$237.9M+544.7%1Y
Net profit
$52.6M
Cash from operations
$170.6M+190.6%1Y
Free cash flow
$156.8M+338.0%1Y
Revenue CAGR, 3Y
-13.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$705.2M$237.9M$52.6M$156.8M10.1%-30.4%-127.6%

Monthly returns

Month-by-month returns of EBS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.3B
Liabilities$796.0M
Equity$522.6M
Paid-in capital$942.4M
Retained earnings-$159.8M
Treasury stock$252.6M

Market cap against peers

8 peers: same sector, nearest by size.

  1. NRC Health$445.1M
  2. Emergent BioSolutions Inc. (this company)$435.5M

Peers map

Healthcare companies placed by value, growth and quality; EBS highlighted.

P/E against peers

EBS trades at 8.3x earnings against a peer median of -4.8x.

  1. Emergent BioSolutions Inc. (this company)8.3x

Not shown (no positive earnings and no EV / Sales): Rezolute, Inc., Neurogene Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Emergent BioSolutions Inc.EBSthis company$435.5M8.3x0.8x10.1%3.4x
NRC HealthNRC$445.1M38.4x31.8x82.9%17.2x
Myriad Genetics, Inc.MYGN$443.0M-1.2x1.2x-99.4%-1.5x
Varex Imaging CorporationVREX$440.9M—0.9x-14.9%973.8x
Evolus, Inc.EOLS$434.6M-8.4x-18.8x223.5%-23.8x
Rezolute, Inc.RZLT$434.3M-5.8x2.7x-45.9%-4.3x
Neurogene Inc.NGNE$434.2M-4.8x1.6x-34.1%-3.9x
ClearPoint Neuro, Inc.CLPT$429.5M-16.8x15.3x-91.1%-21.2x
Orthofix Medical Inc.OFIX$418.0M-4.5x0.9x-20.5%51.8x
Peer median—-4.8x1.4x-27.3%-2.7x

Year-to-date ROI

EBS since 1 January, against earlier years.

Historical volatility

EBS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Emergent BioSolutions Inc. operating margin by fiscal year
Emergent BioSolutions Inc. operating margin by fiscal year
DateOperating margin
FY2022-15.2%
FY2023-19.7%
FY2024-8.0%
FY202515.9%
LineFY2025
Cost of revenueCost Of Revenue$326.2M
Gross profitGross Profit$379.0M
Operating expensesOperating Expense$266.7M
Research and developmentResearch And Development$53.2M
Selling, general and administrativeSelling General And Administration$186.1M
Other operating expensesOther Operating Expenses-$37.7M
Depreciation and amortisationDepreciation And Amortization In Income Statement$65.1M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$65.1M
Amortization$65.1M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$65.1M
Total expensesTotal Expenses$592.9M
Pretax incomePretax Income$82.8M

Learn while you research

Academy chapters picked for Emergent BioSolutions Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 8.3 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →